Association between Rash and a Positive Drug Response Associated with Vinorelbine in a Patient with Primary Peritoneal Carcinoma

Table 1

Summary of hematological events in 365 patients receiving single agent VRL∗†.

Adverse event	All patients (𝑛=365)	NSCLC (𝑛=143)
Bone marrow
Granulocytopenia
<2,000 cells/mm^3	90%	80%
<500 cells/mm^3	36%	29%
Leukopenia
<4,000 cells/mm^3	92%	81%
<1,000 cells/mm^3	15%	12%
Thrombocytopenia
<100,000 cells/mm^3	5%	4%
<50,000 cells/mm^3	1%	1%
Anemia
<11 g/dL	83%	77%
<8 g/dL	9%	1%
Hospitalizations due to granulocytopenic complications	9%	8%

∗None of the reported toxicities were influenced by age. Grade based on modified criteria from the National Cancer Institute.
^†Patients with NSCLC had not received prior chemotherapy. The majority of the remaining patients had received prior chemotherapy
(http://www.fda.gov/ohrms/dockets/ac/04/briefing/4021b1_10_vinorelbine%20label.pdf).